Author:
Coura-Filho George Barberio,Torres Silva de Oliveira Mayara,Morais de Campos Ana Luiza
Publisher
Springer International Publishing
Reference11 articles.
1. Bodei L. Somatostatin receptor scintigraphy: blazing in indium and quenching in gallium (perspective on „Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide“ J Nucl Med. 1992;33:652–658). J Nucl Med. 2020;61(Supplement 2):121S–9S.
2. Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14(74):71–81.
3. Shaverdian N, Pinchot SN, Zarebczan B, Gillis HC, Schiro A, Chen H. Utility of 111 indium-pentetreotide scintigraphy in patients with neuroendocrine tumors. Ann Surg Oncol. 2016;20(2):640–5.
4. Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25(3):251–61.
5. Chiti A, van Graafeiland BJ, Savelli G, Ferrari L, Seregni E, Castellani MR, et al. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S190–4.